Philippe John

Biography

His group was a pioneer in the field of peripheral blood stem cell (PBSC) identification and transplantation and realized the 6th worldwide PBSC graft in 1986. He is member of twelve national and international scientific societies and corresponding member of the New York Academy of Sciences. In 1992, he was co-founder and member of the Board of Directors of the International Society for Hematotherapy and Graft Engineering (now International Society for Cell Therapy). He contributed to peer-reviewed journal editorial boards like Bone Marrow Transplantation, Stem Cells or the Journal of Hematotherapy. European Editor for the “Journal of Hematotherapy and Stem Cell Research” (1999-2003) and for “Stem Cells and Development” (2004-2006). Since 1989, he has actively participated in 25 Scientific Committees in international meetings including 4 meetings of the International Society for Experimental Hematology (ISEH ).)

Research Interest

His group was a pioneer in the field of peripheral blood stem cell (PBSC) identification and transplantation and realized the 6th worldwide PBSC graft in 1986. He is member of twelve national and international scientific societies and corresponding member of the New York Academy of Sciences. In 1992, he was co-founder and member of the Board of Directors of the International Society for Hematotherapy and Graft Engineering (now International Society for Cell Therapy). He contributed to peer-reviewed journal editorial boards like Bone Marrow Transplantation, Stem Cells or the Journal of Hematotherapy. European Editor for the “Journal of Hematotherapy and Stem Cell Research” (1999-2003) and for “Stem Cells and Development” (2004-2006). Since 1989, he has actively participated in 25 Scientific Committees in international meetings including 4 meetings of the International Society for Experimental Hematology (ISEH ).) GlaxoSmithKline (GSK) where he helped advance several products, biologics, as well as small molecule drugs, from early discovery through advanced clinical trials, and post-market product differentiation and line extensions. Dr. Truneh spent over 4 years as Vice President and Senior Vice President of R&D at Antigenics and TolerRx, respectively, where he oversaw programs in cancer, autoimmune and allergic disorders and infectious diseases. Dr. Truneh was Founder and President of Synaptex, Inc., a company focused on the discovery and development of biologics therapies for the treatment of cancer and autoimmune diseases through targets at the immune synapse. He has been a visiting scientist at INSERM/CNRS in France, a fellow of the European Molecular Biology Organization, and Associate Professor of Pharmacy at Marseille University. Dr. Truneh has co-authored over 100 scientific papers and is co-inventor on 30 patents. Dr. Truneh obtained his B.Sc. and Ph.D. in Biochemistry from the University of London.